2.50
Hdl Handle:
http://hdl.handle.net/10541/94703
Title:
Antiestrogens: future prospects.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Tamoxifen is currently the endocrine therapy of choice for early and advanced breast cancer. Attempts to improve the therapeutic efficacy have included altering the triphenylethylene ring structure of tamoxifen, forming new nonsteroidal ring structures or creating steroidal estradiol analogs with greater antiestrogenic activity. There are now six nonsteroidal compounds either on the market or in clinical development and one steroidal "pure" antiestrogen has entered clinical trials. A number of these agents show improved estrogen-receptor binding affinity, antiestrogenic activity, and/or antitumor activity compared with tamoxifen. Preclinical and clinical data on these compounds are discussed and compared with tamoxifen when possible.
Affiliation:
Christie Hospital N.H.S. Trust, Department of Medical Oncology, Manchester, United Kingdom.
Citation:
Antiestrogens: future prospects. 1997, 11 (2 Suppl 1):59-64 Oncology
Journal:
Oncology
Issue Date:
Feb-1997
URI:
http://hdl.handle.net/10541/94703
PubMed ID:
9065930
Type:
Article
Language:
en
ISSN:
0890-9091
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2010-03-23T15:15:17Z-
dc.date.available2010-03-23T15:15:17Z-
dc.date.issued1997-02-
dc.identifier.citationAntiestrogens: future prospects. 1997, 11 (2 Suppl 1):59-64 Oncologyen
dc.identifier.issn0890-9091-
dc.identifier.pmid9065930-
dc.identifier.urihttp://hdl.handle.net/10541/94703-
dc.description.abstractTamoxifen is currently the endocrine therapy of choice for early and advanced breast cancer. Attempts to improve the therapeutic efficacy have included altering the triphenylethylene ring structure of tamoxifen, forming new nonsteroidal ring structures or creating steroidal estradiol analogs with greater antiestrogenic activity. There are now six nonsteroidal compounds either on the market or in clinical development and one steroidal "pure" antiestrogen has entered clinical trials. A number of these agents show improved estrogen-receptor binding affinity, antiestrogenic activity, and/or antitumor activity compared with tamoxifen. Preclinical and clinical data on these compounds are discussed and compared with tamoxifen when possible.en
dc.language.isoenen
dc.subjectOestrogen Antagonistsen
dc.subject.meshEstrogen Antagonists-
dc.subject.meshForecasting-
dc.subject.meshHumans-
dc.subject.meshMolecular Structure-
dc.subject.meshTamoxifen-
dc.titleAntiestrogens: future prospects.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital N.H.S. Trust, Department of Medical Oncology, Manchester, United Kingdom.en
dc.identifier.journalOncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.